NCT06226506View on ClinicalTrials.gov

Comparative Pharmacokinetic Study of Aprepitant Injection in Humans

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

January 23, 2024

Primary Completion Date

January 25, 2024

Study Completion Date

January 25, 2025

Conditions
Healthy
Interventions
DRUG

Test (T) Aprepitant injection

Specification: Aprepitant injection 4.4ml∶32mg. Produced and supplied by Qilu Pharmaceutical (Hainan) Co.

DRUG

Reference (R) Aprepitant injection

Specification: Aprepitant injection 4.4ml∶32mg. Produced by Heron Therapeutics, Inc and supplied by Qilu Pharmaceutical (Hainan) Co.

All Listed Sponsors
lead

The Affiliated Hospital of Qingdao University

OTHER